COLUMBUS, Ohio – A new study shows that loss of a small RNA molecule in liver cells might cause liver cancer and that restoring the molecule might slow tumor growth and offer a new way to treat the disease.
The animal study was led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
The scientists examined what happens when liver cells lack a molecule called microRNA-122 (miR-122). They found that when the molecule is missing, the liver develops fat deposits, inflammation and tumors that resemble hepatocellular carcinoma (HCC), the most common form of liver cancer.
When the researchers artificially restored miR-122 to nearly normal levels by delivering the miR-122 gene into liver cells, it dramatically reduced the size and number of tumors, with tumors making up 8 percent on average of liver surface area in treated animals versus 40 percent in control animals.
The study is published in the Journal of Clinical Investigation with an accompanying commentary.
"These findings reveal that miR-122 has a critical tumor-suppressor role in the healthy liver, and they highlight the possible therapeutic value of miR-122 replacement for some patients with liver cancer," says study leader Dr. Kalpana Ghoshal, associate professor of pathology and a member of the OSUCCC – James Experimental Therapeutics Program.
More than 28,700 new cases of HCC are expected in the United States in 2012, and 20,550 Americans are expected to die of the malignancy. Major risk factors for HCC include hepatitis B and C virus infection and liver damage due to alcohol use. HCC is curable if caught early, but most cases are diagnosed at a late, incurable stage.
MiR-122 is found mainly in liver cells – it is the most abundant microRNA in those cells – and it plays a major role in regulating cholesterol in the body. This microRNA is lost in some people with HCC, however, resulting in a poor prognosis.
For this study, Ghoshal and her colleagues developed a strain of mice that lacks miR-122 and develops HCC through the progression of events that begins with fatty liver deposits followed by inflammation and liver cancer.
The researchers then used a second strain of mice that spontaneously develops liver cancer due to overexpression of a cancer-causing gene called MYC (pronounced "mick"). The researchers delivered miR-122 into the animals' livers during tumor development. Three weeks later, those treated with the molecule had smaller and fewer tumors.
"The model we developed for these studies will not only facilitate our understanding of liver biology but also be good for testing therapeutic efficacy of newly developed drugs against liver disease, including HCC," Ghoshal says.
Ghoshal also notes that research by others has shown that hepatitis C virus requires miR-122 for replication. "Because our findings demonstrate what happens when miR-122 is lost in liver cells, they might help improve the safety of new drugs that treat hepatitis C virus infection by blocking miR-122," she says.
Funding from the NIH/National Cancer Institute (grants CA086978, CA120185 and CA134292), NIH/ National Institute of Diabetes and Digestive and Kidney Diseases (grant DK088076), a Pelotonia idea grant, a Pelotonia predoctoral fellowship, and the Cancer Prevention and Research Institute of Texas supported this research.
Other researchers involved in this study were Shu-hao Hsu, Bo Wang, Jianhua Yu, Stefan Costinean, Huban Kutay, Lianbo Yu, Shoumei Bai, Krista La Perle, Hsiaoyin Mao, Min Wei, Michael A. Caligiuri and Samson T. Jacob of The Ohio State University; Janaiah Kota, K. Reed Clark and Jerry R. Mendell of Nationwide Children's Hospital; Raghu R. Chivukula of Johns Hopkins University School of Medicine; and Joshua T. Mendell of UT Southwestern Medical Center.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S.News & World Report.
Contact: Darrell E. Ward, Medical Center Public Affairs and Media Relations,
614-293-3737, or Darrell.Ward@osumc.edu